Turning Point Therapeutics, Inc.
TPTX · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $1,948 | $4,977 | $1,503 | $432 |
| - Cash | $428 | $554 | $48 | $101 |
| + Debt | $6 | $4 | $5 | $0 |
| Enterprise Value | $1,526 | $4,427 | $1,460 | $331 |
| Revenue | $31 | $25 | $0 | $0 |
| % Growth | 23.3% | – | – | – |
| Gross Profit | $31 | $0 | $0 | $0 |
| % Margin | 100% | 0% | – | – |
| EBITDA | -$233 | -$155 | -$71 | -$25 |
| % Margin | -754.4% | -619.6% | – | – |
| Net Income | -$237 | -$157 | -$72 | -$25 |
| % Margin | -767.3% | -629.2% | – | – |
| EPS Diluted | -5.79 | -3.85 | -2.99 | -1.66 |
| % Growth | -50.4% | -28.8% | -80.1% | – |
| Operating Cash Flow | -$154 | -$83 | -$58 | -$24 |
| Capital Expenditures | -$2 | -$1 | -$2 | -$0 |
| Free Cash Flow | -$156 | -$84 | -$60 | -$24 |